Status:
COMPLETED
Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients
Lead Sponsor:
Baskent University
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
49-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure-reducing effects.
Detailed Description
The first study to evaluate the effects of troglitazone on blood pressure in humans was published recently, which demonstrated a 5/4 mm Hg reduction in ambulatory blood pressure in 18 nondiabetic obes...
Eligibility Criteria
Inclusion
- Blood pressure of patients were in normotensive limits according to the JNC VII
- Diabetes mellitus treated with oral antidiabetics or diet
Exclusion
- Any known hypertension, coronary artery disease, congestive hearth failure, renal disease or liver disease
- Anti-hypertensive treatment
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2004
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00290394
Start Date
March 1 2004
End Date
August 1 2004
Last Update
February 13 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baskent University Ankara Hospital
Ankara, Turkey (Türkiye), 06490